- Conditions
- Diabetic Retinopathy
- Interventions
- doxycycline monohydrate, Placebo
- Drug
- Lead sponsor
- Thomas Gardner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 80
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Degeneration
- Interventions
- Lucentis, Ranibizumab, Ranibizumab (Lucentis)
- Drug
- Lead sponsor
- The National Retina Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Chevy Chase, Maryland • Towson, Maryland
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
- Interventions
- INV-102
- Drug
- Lead sponsor
- Invirsa, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Retinopathy of Prematurity, Retinal Detachment, Blindness
- Interventions
- ACULAR, REFRESH TEARS, placebo
- Drug
- Lead sponsor
- University of South Alabama
- Other
- Eligibility
- 10 Days to 15 Days
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Mobile, Alabama
- Conditions
- Diabetic Retinopathy
- Interventions
- doxycycline monohydrate, placebo
- Drug
- Lead sponsor
- Thomas Gardner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Proliferative Diabetic Retinopathy (PDR)
- Interventions
- Aflibercept 8mg
- Drug
- Lead sponsor
- Edward Wood, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Austin, Texas • Bellaire, Texas • San Antonio, Texas
- Conditions
- Proliferative Vitreoretinopathy
- Interventions
- Methotrexate
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 1467335, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more
- Conditions
- Diabetic Macular Edema
- Interventions
- 0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 3
- States / cities
- Houston, Texas • Katy, Texas • The Woodlands, Texas
- Conditions
- Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
- Interventions
- Netarsudil Ophthalmic
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Interventions
- APX3330, Placebo
- Drug
- Lead sponsor
- Opus Genetics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Interventions
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- 1.0mg Luminate®, 2.0mg Luminate®, 3.0mg Luminate®, Balanced Salt Solution for intravitreal injection in 0.10cc
- Drug · Other
- Lead sponsor
- Allegro Ophthalmics, LLC
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Mountain View, California • Orange, California • New London, Connecticut + 9 more
- Conditions
- Rubeosis Iridis, Proliferative Diabetic Retinopathy
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Bhagat, Neelakshi, M.D., M.P.H.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Epiretinal Membrane, Macular Hole, Visually Significant Vitreous Floater, Vitreomacular Traction, Vitreous Hemorrhage, Proliferative Diabetic Retinopathy, Rhegmatogenous Retinal Detachment, Retained Lens Material in the Posterior Segment
- Interventions
- UNITY Vitreoretinal Cataract System (VCS), CONSTELLATION Vision System, Vitreoretinal ophthalmic surgery
- Device · Procedure
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Laguna Hills, California • West Des Moines, Iowa + 5 more
- Conditions
- Proliferative Diabetic Retinopathy - High Risk
- Interventions
- laser indirect ophthalmoscopy pan retinal photocoagulation
- Procedure
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Retinal Detachment, Vitrectomy, Proliferative Vitreoretinopathy, Diabetic Retinopathy
- Interventions
- 1000 centistoke silicone oil, 5000 centistoke silicone oil
- Procedure
- Lead sponsor
- Mid Atlantic Retina
- Other
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Macugen, Sham
- Drug
- Lead sponsor
- Greater Houston Retina Research
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Interventions
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Campbell, California • Irvine, California + 6 more
- Conditions
- Diabetic Retinopathy
- Interventions
- OTT166, Vehicle control
- Drug
- Lead sponsor
- OcuTerra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 67
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more
- Conditions
- Proliferative Vitreoretinopathy
- Interventions
- Isotretinoin
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Macugen ® (pegaptanib sodium)
- Drug
- Lead sponsor
- Valley Retina Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- McAllen, Texas
- Conditions
- Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy, Severe Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- Not listed
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Hilo, Hawaii
- Conditions
- Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
- Interventions
- Faricimab Injection, sham treatment
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado